Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.38 -0.95%
EPS Growth %: -31.3%
Financial Fact:
Interest income: 358K
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -31.3%
Financial Fact:
Interest income: 358K
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Tops Q1 EPS by 18c
- Alcoa agrees to buy South32 assets for $4.1 billion
- Jefferies Upgrades Murphy USA (MUSA) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
